Clinical trials: PD-L1 Positive
PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
This is a multicenter, randomized, open-label, international, Phase 3 trial to evaluate the efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel (standard of care) in participants with locally…
- Trial name
- NCT06635824
- Testing
- Acasunlimab, Pembrolizumab, Docetaxel
- Where
- 247 sites in United States, Argentina and 25 more
- Volunteers
- 191 people
- Sponsor
- Genmab
Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive
A Phase 2 Study of ABSK043 Combined With Osimertinib
This is a phase 2, open-Label study to evaluate the efficacy and safety of ABSK043 Combined with Osimertinib in participants with EGFR-Mutated locally advanced or metastatic Non-Small Cell Lung Cancer
- Trial name
- NCT07710612
- Testing
- ABSK043 in combination with Osimertinib
- Where
- 7 sites in China
- Volunteers
- 72 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
This study is to evaluate the progression-free survival (PFS) of SHR-A1811 combined with SHR-1316 in the first-line treatment of PD-L1-positive locally recurrent unresectable or metastatic triple-negative breast cancer with…
- Trial name
- NCT07111832
- Testing
- SHR-A1811 for Injection, SHR-1316 Injection, Toripalimab Injection
- Where
- 2 sites in China
- Volunteers
- 400 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Triple Negative Breast Cancer, PD-L1 Positive
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with…
- Trial name
- ASCENT-04 (NCT05382286)
- Testing
- Sacituzumab Govitecan-hziy, Pembrolizumab, Paclitaxel
- Where
- 504 sites in United States, Argentina and 26 more
- Volunteers
- 443 people
- Sponsor
- Gilead Sciences
Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
This study is a randomised, double-blind, placebo-controlled, multicentre phase 3 clinical study to evaluate the efficacy and safety of SG001 plus chemotherapy±bevacizumab versus placebo plus chemotherapy±bevacizumab, as…
- Trial name
- NCT05715840
- Testing
- SG001 injection, Paclitaxel, Cisplatin
- Volunteers
- 368 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced PD-L1 Positive Malignancies
Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive Malignancies
The primary objective of the study is to determine the safety and tolerability of 89Zr-DFO-REGN3504. The secondary objectives of the study are: Study Part A only: To establish adequate mass dose and activity dose of…
- Trial name
- NCT03746704
- Testing
- 89Zr˗DFO˗REGN3504
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Regeneron Pharmaceuticals
Stage IV Non-small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer
Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy
The current study is aimed to test the benefit of a web-based application tool in NSCLC, SCLC and TNBC patients during the recently approved first-line treatment strategy with atezolizumab in combination with chemotherapy.
- Conditions
- Stage IV Non-small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer, Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC
- Trial name
- CHAPLIN (NCT03911219)
- Testing
- eHealth system support for symptom management via CANKADO
- Where
- 92 sites in Germany
- Volunteers
- 154 people
- Sponsor
- iOMEDICO AG
Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN
Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus SoC therapy in the target patient…
- Trial name
- EAGLE (NCT02369874)
- Testing
- MEDI4736, MEDI4736 + Tremelimumab, Standard of Care
- Where
- 168 sites in United States, Argentina and 22 more
- Volunteers
- 736 people
- Sponsor
- AstraZeneca
Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck
Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Primary Objective: To assess the efficacy of MEDI4736 monotherapy in terms of ORR
- Trial name
- NCT02207530
- Testing
- MEDI4736
- Where
- 108 sites in United States, Belgium and 12 more
- Volunteers
- 112 people
- Sponsor
- AstraZeneca
PD-L1 Positive Non-small Cell Lung Cancer
Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)
The study is being conducted to evaluate the efficacy and safety of Camrelizumab (200mg,q2w) combined with Apatinib(250mg qd) in subjects with PD-L1 positive relapsed or advanced non-small cell lung cancer.
- Trial name
- NCT04203485
- Testing
- Camrelizumab 200mg, Apatinib Mesylate 250mg, Pemetrexed disodium for injection
- Volunteers
- 762 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.